-transparent.png){kind=logo}
Thirty-four patients with progressive low grade non-Hodgkin's lymphoma were treated with 1 microgram oral alfacalcidol daily. Complete response was seen in four patients and a partial response in four patients with an overall response rate of 24%. Median duration of response was 14 months. Disease stabilised in ten other patients (29%) and 16 patients (47%) had tumour progression. In the sub-group of patients with follicular, small-cleaved cell-lymphoma the overall response to treatment was 29%. Apart from one patient who had a mild transitory elevation of serum calcium there was no recorded toxicity from alfacidol. These results indicate that alfacalcidol has significant antitumour activity in patients with low grade non-Hodgkin's lymphoma of the follicular, small-cleaved cell type.
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
January 1987,
Voprosy onkologii,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
January 1989,
Urologia internationalis,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
December 1991,
Sangre,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
September 1996,
Mayo Clinic proceedings,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
July 1994,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
August 1983,
Journal of occupational medicine. : official publication of the Industrial Medical Association,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
December 1994,
Fukushima journal of medical science,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
September 1985,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
February 2018,
Human pathology,
V Raina, and
D Cunningham, and
N Gilchrist, and
M Soukop
September 1990,
Cancer genetics and cytogenetics,
